Aldoss, I
Bargou, R C
Nagorsen, D
Friberg, G R
Baeuerle, P A
Forman, S J
Article History
Received: 13 September 2016
Revised: 30 November 2016
Accepted: 5 December 2016
First Online: 28 December 2016
Competing interests
: IA has received consultancy fees from Helocyte Inc. RCB has received patents/royalties for blinatumomab from Amgen Inc and consultancy fees from Amgen Inc, Novartis, Pfizer, AstraZeneca, and GEMoaB GmbH. DN and GRF are currently employed by and hold stock in Amgen Inc; DN is an inventor on blinatumomab-related patents from Amgen Inc. PAB has been an employee of and holds stock in Amgen Inc. SJF reports clinical trial support from Amgen Inc and licensed patents for CAR development related to CD123 on AML and IL13ra2 on brain tumors to Mustang Therapeutics.